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SUMMARY
In high dosage, carbenicillin may interfere with the con-
version of fibrinogen to fibrin and result in a haemorrhagic
diathesis. The effect is dose-dependent and requires a
high concentration of carbenicillin in plasma. Such a level
may be attained in renal failure unless the dose of the
drug is appropriately reduced. In such situations the
screening coagulation tests may be prolonged and this
should alert one to the development of a haemorrhagic
diathesis due to the drug.
s. Afr. Med. J., 48, 457 (1974).
Carbenicillin (a-carboxybenzylpenicillin, Pyopen) is a semi-
synthetic penicillin which is of particular value in the
therapy of infections caused by the Pseudomonas aerugi-
nosa organism. It has been reported to be free from renal,
haematological or neurological side-effects, even in high
doses (30 g/day).' The majority of Ps. aeruginosa strains
are inhibited by a carbenicillin concentration of 100 jLg/
m!.'·' To achieve this level in the serum of patients with
normal renal function, it is necessary to administer 1 g
carbenicillin intravenously every hour (24 g/day) together
with probenecid.' In patients with severe renal failure a
dose of 2 g intravenously every 4 hours (12 g/day) is
recommended if the patient is on haemodialysis, or 2 g
intravenously every 8 hours (6 g/day) if the patient is
on peritoneal dialysis.'
A patient with severe renal failure who was receiving
24 g carbenicillin per day developed severe and persistent
haemorrhagic episodes while taking the drug. Because of
this, 2 more patients in severe renal failure and with
Ps. aeruginosa infections, to whom carbenicillin was to be
administered, were studied before, during and after with-
drawal of the drug. This report documents the coagu-
lation findings on the plasma of these patients, as well
as in vitro studies on normal and uraemic plasma to which
carbenicillin was added.
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CASE REPORTS
Case 1 (Fig. 1)
A 20-year-old male with end-stage renal failure and
malignant hypertension caused by diffuse membranous
glomerulonephritis (confirmed on renal biopsy) was placed
on peritoneal dialysis because of uraemia, acidosis, oli-
guria and fluid overload. Dialysis was continued for 8
days, after which the blood urea was 65 mg/lOO ml, the
hypertension was controlled and the acidosis corrected.
While on dialysis the patient developed peritonitis and
Ps. aeruginosa was cultured from the peritoneal effluent.
Treatment with carbenicillin (24 g/day) and gentamicin
(40 mg/72 h) was begun 4 days after the peritoneal dialy-
sis had been completed. At this time the patient's blood
urea was 170 mg/IOO ml and he was oliguric. Nine days
later when the blood urea was 240 mg/lOO ml, the serum
creatinine level 22,5 mg/IOO ml and the urinary output
240 ml/24 h a Scribner shunt was inserted. Haemodialysis.
which commenced on the following day, was carried out
every 48 - 72 h. Carbenicillin and gentamicin therapy
was continued at the same dosage. Profuse bleeding
occurred from the shunt site shortly after it had ·been
inserted. Predialysis blood urea concentrations were appro-
ximately 120 mg/lOO ml and postdialysis blood urea
concentrations 80 mg/IOO ml. After 13 days on carbeni-
cillin and gentamicin therapy, melaena occurred. The
patient remained pyrexial throughout the period of anti-
biotic therapy and evidence of peritoneal irritation per-
sisted. After 23 days of antibiotic therapy the peritonitis
appeared to have become localised to the right iliac fossa
and a laparotomy was performed to evacuate a palpable
mass in the right iliac fossa. This was found to be a
partially organised retroperitoneal haematoma. Gentamicin
was withdrawn 2 days after laparotomy but carbenicillin
was continued for a further 7 days. During the postopera-
tive period, the patient bled profusely from the abdominal
wound, necessitating replacement transfusions. The bleed-
ing ceased within 2 days after discontinuing the carbeni-
cillin therapy.
Case 2 (Fig. 2)
In a 53-year-old female with end-stage renal failure
caused by analgesic nephropathy and papillary necrosis,
Ps aeruginosa was cultured from the urine. Carbenicillin
therapy was instituted. 24 g/day intravenously for 9
days and 12 g/day for a further 5 days. The patient was
not dialysed. The blood urea ranged from 145 to 300 mg/
100 ml and urinary output from 125 to I 650 ml/24 h.
During this period the patient developed painful haemor-
rhagic excoriations on her lips and tongue.
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Case 3 (Fig. 3) time, KCCT). Coagulation factor assays were, however.
normal.
In a 35- year-old female with analgesic nephropathy and
renal failure the blood urea was stable at 110 mgflOO ml,
serum creatinine 10 mg/lOO ml, urinary output 1000-
2 000 ml/24 h. The patient was not dialysed. Carbenicillin
therapy (24 g/day for 5 days) was instituted for Ps.
aeruginosa and E. coli urinary tract infections. During
therapy the patient developed menorrhagia, haemorrhagic
excoriations on her tongue, headache, and confusion.
MATERIAL AND METHODS
Clotting Tests on Patients' Plasma
The following standard techniques were used: prothrom-
bin time;' kaolin cephalin clotting time (KCCT) (Diagnostic
Reagents Ltd, Thame, Oxon.); prothrombin consumption
index;' fibrinogen;S 2-stage prothrombin;" factor V;]JJ factor
VIII;" and factor X."
Case 1 (Fig. 1)
Coagulation studies were first carried out after 14 days
of carbenicillin therapy (24 g/day).
The prothrombin time was 26,3 s (normal control 14,7 s).
The KCCT was 93,9 s (normal control 51,4 s). Assays of
factors common to both the extrinsic and intrinsic coagu-
lation pathways, namely factors I, 11, V and X were
normal. The factor VIII assay gave a low result (4%).
A repeat test 11 days later, when the patient was still
receiving 24 g carbenicillin/day, showed similar abnormai
screening tests (prothrombin time 24,5 s, normal control
12,5 s; KCCT 135 s, normal control 50,2 s) yet normal
specific factor assays (fibrinogen 420 mg/lOO ml, normal
control 205 ml/lOO ml; factor 11 116%, factor V 90%;
normal range 50 - 150%). The factor VIII assay on
DAYS
IS 25 35
















DIAlYSIS J6 J ! ! ~ g1!! U
z %
~ 0
::~ I I I: I J'HOEA
o[~-~.~~.~~ll.IJl ••••"" ~.~'u'ud..I~' _
Various concentrations of carbenicillin "Were tested in
the following clotting test systems: thrombin conversion
of fibrinogen to fibrin; kaolin cephalin clotting time;
and prothrombin time.
The ability of a fibrin clot to withstand lysis in 5M
urea was tested, in the presence of carbenicillin. In
addition, the effects of protamine sulphate and penicillinase
on the carbenicillin-induced coagulation changes in nor-
mal plasma were studied.
Carbenicillin Assay
In Vitro Clotting Tests
RESULTS
Concentrations of carbenicillin were determined by the
cup-plate biological assay method, using Ps. aeruginosa
TC TC 10490 as the test organism. Bacto'-Antibiotic
Agar No. 2, pH 6,5 - 6,6, was seeded with 0,05% of an
overnight broth culture and poured into large rectangular
assay plates using the layer technique.
Plugs of agar were removed to give holes 7 mm in
diameter which were filled with the solutions to be assayed.
The plates were then incubated overnight at 30°C.
Standard curves were drawn, using carbenicillin 2, 10,
20 and 50 ,u.g/ml dissolved in pooled human serum, or
0,05M phosphate buffer (pH 7,0) for urine assays. The
patients' serum specimens were diluted in pooled human
serum to give levels within this range of concentration.
Urine specimens were diluted in 0,05M phosphate buffer
(pH 7,0).
The results of the clotting tests on the patients' plasma
are shown in Figs I - 3
Each of the patients studied showed clotting abnor-
malities of the screening coagulation tests (prothrombin
CARBENICILLIN
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Fig. 1. Clinical course and coagulation studies on case 1.
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This patient, too, was treated on 24 g carbenicillin/day
for 5 days. Coagulation studies before administration of
the antibiotic were normal. On the 3rd day of treatment,
the prothrombin time was prolonged, 17,5 s (normal
control 14,9 s) and the KCCT minimally prolonged, 62,9 s
(normal control 56,7 s). A serum carbenicillin level one
hour after administration of the drug was 3 194 fLg/ml,
and 1 597 p.g/ml 5 hours after administration. The drug
was then withdrawn, and therapy recommenced 3 days
later at 6 g/day for 5 days. Repeat coagulation studies
1 day after the completion of the 6 g/day course of
treatment were normal. Menorrhagia occurred after 2
days of 24 g/day carbenicillin therapy. Renal function
was reduced to a creatinine clearance of 10 ml/min.
Urine output was, however, adequate, and the patient was
not dialysed,
Carbenicillin clearance was calculated on one occasion.
A serum level of 12,5 p.g/ml and urine level of 399
p.g/ml were obtained, which gave a calculated carbenicillin
clearance of 40 ml/min. Since the creatinine clearance
done at the same time was 10 ml/min, a tubular secretion
of the drug is suggested.
Case 3 (Fig, 3)
Fig. 3, Clinical course and coagulation studies on case 3.
Results of in Vitro Tests
Thrombin times: Doubling and tenfold dilutions of
carbenicillin in normal plasma were tested in a calcium-
thrombin system. Prolongation of thrombin clotting times
were noted at concentrations of carbenicillin of 6250 p.g/




















this occasion was at the upper limit of normal (158%)..
Two days after the drug was withdrawn, the prothromQin
time and KCCT were only slightly abnormal (prothrombin
time 14,0 s, normal control 12,5 s; and KCCT 65,5 s,
normal control 47,6 s). The KCcr returned to normal
values one day later (56,9 s, normal control 51,7 s).
The prothrombin time remained minimally prolonged
(15,0 s, normal control 13,8 s).
Fig. 2. Clinical course and coagulation studies on case 2,
Case 2 (Fig. 2)
Coagulation studies before carbenicillin therapy showed
a prothrombin time of 14,5 s (normal control 12 s) and
KCcr of 44,4 s (normal control 50,2 s). The fibrinogen
level was 630 mg/l00 ml (normal 200 - 400 mg/l00 m!).
Six days after the commencement of carbenicillin therapy
at a dose of 24 g/day, the prothrombin time was 17,4 s
(normal control 13,3 s) and the KCcr 88,2 s (normal
<:ontrol 51,0 s). The plasma fibrinogen remained elevated
(630 mg/l00 ml). After g- days' carbenicillin therapy
(24 g/day), the prothrombin time was 19,5 s (normal
control 12,4 s) and KCCT 109,3 s (normal control 54,8 s).
The fibrinogen level was then 716 mg/lOO ml and factors
II, V and X were normal. The factor VIII assay was
normal (125~o). ine days after discontinuing the drug,
the KCCT was normal (53,6 s, normal control 45,6 s),
although the prothrombin time remained prolonged (22,1
s, normal control 12,4 s). The patient died 12 days after
cessation of carbenicillin therapy from renal failure and
septicaemia.
The serum carbenicillin level was measured one hour
after the administration of a 6-g dose on the third day
-of the course of therapy. A serum carbenicillin level of
1 597 p.g/ml was obtained. The patient's blood urea at
this stage was 200mgjlOO ml. Nine days after cessation of
-carbenicillin therapy, a serum carbenicillin level of 62
p-g/ml was obtained.
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concentration of carbenicillin in the test system was
high enough.
Effect of penicillinase (Table I): A concentration of
carbenicillin sufficient to cause an abnormal thrombin
time (10 000 flg/ml) was added to normal plasma. To this
was added a penicillinase concentration theoretically
capable of neutralising 10000 flg penicillin. No reduction
in the abnormal thrombin clotting times was detected at
o min and after 60 min incubation of the plasma mixtures
at 37"C.
Effect of protamine sulphate (Table Il): The effect of
protamine sulphate on normal plasma containing carbeni-
cillin (25000 flg/m!) Jr heparin (l unit/m!) was studied.
No neutralisation of the abnormal KCCT was observed
when a range of protamine sulphate concentrations was
added to normal plasma containing th~ carbenicillin.
Heparinised plasma was neutralised by I mg protamine





























Fig. 4. Effect of increasing concentrations of carbenicillin
















Fig. 6. Effect of increasing concentrations of gentamicin
sulphate on the thrombin time of normal plasma.
Effect of gentamicin sulphate and carbenicillin on the
thrombin time of normal plasma (Fig. 6 and Table Ill):
Since patient 1 was receiving gentamicin sulphate as
well as carbenicillin, the effect of increasing concentrations
of gentamicin on the thrombin time of normal plasma
was tested. This was compared with the anticoagulant effect
of carbenicillin alone and carbenicillin together with gen-
tamicin. Concentrations of gentamicin from 0,8 flg/ml to
2000 flg/ml had no anticoagulant effect. At concentrations
of 8 000 flgJml gentamicin was found to have an additive
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Fig. 5. Effect of increasing concentrations of carbenicillin
on the KCCT of normal plasma using M/40 CaCl,
(0,025M) and M/20 CaC1 2 (0,051\1).
gulant effect of carbenicillin was detected when the drug
was added to uraemic plasma.
As a result of the prolongation of the thrombin
clotting time by carbenicillin, all tests dependent on this
final stage of fibrin formation were abnormal. Thus the
KCCT (Fig. 5), thromboplastin generation test, and re-
calcification time of plasma were abnormal, provided the
DISCUSSION
Carbenicillin has been found to be a safe and effective
preparation for the therapy of Ps. aeruginosa infections.'
Plasma levels inhibitory to these organisms appear to be
in the region of 100 flg/mI.'·' At this plasma concentration,
no haemorrhagic side-effects have been noted. The dosage
recommended to achieve this level is 24 - 30 g daily.
In renal failure, however, lower dosages are recommended
(6- 8 g daily) to achieve the same therapeutic level.
Three patients with renal failure were treated with high
doses of carbenicillin. In 1 patient severe bleeding
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TABLE I. EFFECT OF PENICILLINASE ON THE THROMBIN TIME OF NORMAL PLASMA WITH AND WITHOUT ADDED
CARBENICILLIN
Thrombin time (s)
Incubation at Carbenicillin Carbenicillin +
37°C (min) Control (10 000 p..g/ml) Penicillinase penicillinase
0 9,0 63,8 10,0 58,0
60 9,6 63,5 9,8 66,2
0.2 ml 0.025M CaCI, (4 parts)/thrombin 50 units/ml (1 part) was add&d to a mixture of 0.4 ml nor-
mal plasma. 0,1 rnl carbenicillin dilution, an(i the clotting times recorded. The mixtures were tested
at 0 min and after 60 min incubation at 37°C. As a control. 0.2 ml buffer was added to the
normal plasma instead of the carbenicillin and penicillinase solutions.
TABLE Ill. EFFECT OF GENTAMICIN SULPHATE AND
CARBENICILLIN ON THE THROMBIN TIME OF NORMAL
PLASMA
TABLE 11. EFFECT OF PROTAMINE SULPHATE ON THE KCCT
OF NORMAL PLASMA WITH ADDED HEPARIN OR
CARBENICILLIN
KCCT of plasma without added heparin or Carbenicillin = 69,1 s.
0.2 ml kaolin/cephalin suspension was added to 0,1 ml plasma con-
taining heparin 1 Jlg/ml or carbenicillin 25000 Jlg/ml, and 0,1 ml prota-
mine sulphate concentra.ion. The mixture was incubated for 2 min,
then recalcified with 0,1 ml 0,025M Ca Cl" and the dottinR times
recorded.
Reaction mixture
Due acknowledgement is made to the Atomic Energy Board
and the South African Medical Research Council for the
assistance and support enabling the research to be undertaken.
extrinsic systems were abnormal (prothrombin time and
KCCT), yet assays of specific factors common to both
pathways were normal. This suggested an anticoagulant
effect which was detected by the screening tests but not
by specific factor assays. These latter assay procedures
utilise diluted plasma, whereas the prothrombin time
and KCCT procedures use relatively concentrated plasma.
If an anticoagulant were present in the plasma it could
therefore interfere with the screening coagulation tests,
but its effect might be diluted out in the factor assays.
The anticoagulant effect was demonstrated in vill'o
by adding increasing concentrations of the drug to normal
plasma. The greater the concentration of the drug in
plasma, the greater was the anticoagulant effect. This
effect could be reduced by reducing the concentration
of the drug or by increasing the volume of the plasma.
The anticoagulation was found to be due to an inter-
ference in the conversion of fibrinogen to fibrin. -The
mode of action of this interference has not been estab-
lished. If the concentration of carbenicillin in plasma is
high enough, all tests dependent on the conversion of
fibrinogen to fibrin are abnormal.
The serum level obtained in the second patient studied
(I 597 p..g/ml), is far in excess of that required for therapy
of Pseudomonas infections (lOO p..g/ml). Thus it is unlikely
that such levels will be attained, provided the therapeutic
dose is reduced in the presence of renal insufficiency. If
not, a bleeding diathesis may ensue, which may present a
















































0,2 ml O,025M CaCI, (4 parts)/thrombin 50 units/ml (1 part) was
added to a mixture containing 0.3 ml normal plasma, 0,1 ml genta-
micin dilution and 0,1 carbenicillin dilution and the clottin!=} times
recorded. As a control 0,2 ml buffer was added instead of the anti-
biotic solutions.
occurred from the bowel, Scribner shunt site, retroperi-
toneal space and abdominal wound. The bleeding ceased
when the carbenicillin was withdrawn. Two further
patients developed abnormalities of their screening clotting
tests when carbenicillin was administered. These returned
to normal when the drug was withdrawn. In all 3 patients
the screening coagulation tests of the intrinsic and
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